Aspen Pharmacare expects to be ready to launch at market formation for its proposed semaglutide generics after achieving “confidence now in both the quality and acceptability of [our] dossiers,” having made “significant progress” in positioning itself as an owner of the intellectual property, a manufacturer, and in “establishing the appropriate marketing and distribution reach.”
Aspen Believes It ‘Ticks All The Boxes’ As It Begins Submitting GLP-1 Dossiers
‘Our IP Is Good – But Now We Have Confidence In Submissions,’ Aspen Says
South Africa’s Aspen Pharma has discussed the “significant progress” it believes it has made in GLP-1s, with an eye on rolling-out semaglutide in non-US and non-EU markets beginning as early as 2026.
More from Earnings
• By
The Chinese player reported its second profitable year in a row, with growth in sales reported across its marketed portfolio and further milestones in the near future.
• By
After announcing updates in its ongoing legal battle and a leadership shakeup earlier this fiscal year, Hyloris closed 2024 with a slight rise in revenue and a shrinking of its reported net loss.
• By
Months on from penning a landmark commercial and manufacturing agreement for GLP-1 assets with Metsera, Amneal says it is happy with how the partnership is shaping up.
• By
Stada has set out annual results that it says demonstrate that the German firm is outperforming the market in all of its business segments, with the company breaking the €4bn sales barrier for the first time. The results come ahead of a long-awaited potential IPO that conflicting rumors suggest could either come very soon indeed, or may be delayed until later this year.
More from Strategy
• By
Months on from penning a landmark commercial and manufacturing agreement for GLP-1 assets with Metsera, Amneal says it is happy with how the partnership is shaping up.
• By
Sweden’s Xbrane has struck a deal to transfer its R&D operations in Sweden and its Cimzia (certolizumab pegol) biosimilar candidate to Alvotech, in a transaction worth around $27m. However, Xbrane told Generics Bulletin that it was not getting out of biosimilar development altogether.
• By
Stada has set out annual results that it says demonstrate that the German firm is outperforming the market in all of its business segments, with the company breaking the €4bn sales barrier for the first time. The results come ahead of a long-awaited potential IPO that conflicting rumors suggest could either come very soon indeed, or may be delayed until later this year.